Evidence map›Paper›PMID 33657179›Full record

ArticlePloS one2021

Efficacy of indoor residual spraying with broflanilide (TENEBENAL), a novel meta-diamide insecticide, against pyrethroid-resistant anopheline vectors in northern Tanzania: An experimental hut trial.

Janneke Snetselaar, Mark W Rowland, Baltazari J Manunda, Ezekia M Kisengwa, Graham J Small, David J Malone, Franklin W Mosha, Matthew J Kirby

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Janneke SnetselaarLondon School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0002-5882-6855
Mark W RowlandLondon School of Hygiene & Tropical Medicine, London, United Kingdom.
Baltazari J ManundaKilimanjaro Christian Medical University College, Moshi, Kilimanjaro, Tanzania.
Ezekia M KisengwaKilimanjaro Christian Medical University College, Moshi, Kilimanjaro, Tanzania.
Graham J SmallInnovative Vector Control Consortium, Liverpool, United Kingdom.
David J MaloneInnovative Vector Control Consortium, Liverpool, United Kingdom.
Franklin W MoshaKilimanjaro Christian Medical University College, Moshi, Kilimanjaro, Tanzania.
Matthew J KirbyLondon School of Hygiene & Tropical Medicine, London, United Kingdom.ORCID 0000-0001-5470-1433
Kilimanjaro Christian Medical Centre · TZLondon School of Hygiene & Tropical Medicine · GBInnovative Vector Control Consortium · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel chemistry for vector control is urgently needed to counter insecticide resistance in mosquitoes. Here a new meta-diamide insecticide, broflanilide (TENEBENALTM), was evaluated in East African experimental huts in Moshi, northern Tanzania. Two consecutive experimental hut trials with broflanilide 50WP were conducted; the first evaluating the efficacy of three concentrations, 50 mg/m2, 100 mg/m2, and 200 mg/m2 using a prototype formulation, and the second trial evaluating an improved formulation. The IRS treatments were applied on both mud and concrete surfaces and efficacy was monitored over time. The mortality, blood-feeding inhibition and exiting behaviour of free-flying wild mosquitoes was compared between treatment arms. Additionally, cone assays with pyrethroid-susceptible and resistant mosquito strains were conducted in the huts to determine residual efficacy. The first trial showed a dosage-mortality response of the prototype formulation and 3-8 months of residual activity, with longer activity on concrete than mud. The second trial with an improved formulation showed prolonged residual efficacy of the 100 mg/m2 concentration to 5-6 months on mud, and mosquito mortality on the concrete surface ranged between 94-100% for the full duration of the trial. In both trials, results with free-flying, wild Anopheles arabiensis echoed the mortality trend shown in cone assays, with the highest dose inducing the highest mortality and the improved formulation showing increased mortality rates. No blood-feeding inhibition or insecticide-induced exiting effects were observed with broflanilide. Broflanilide 50WP was effective against both susceptible and pyrethroid-resistant mosquito strains, demonstrating an absence of cross resistance between broflanilide and pyrethroids. The improved formulation, which has now been branded VECTRONTM T500, resulted in a prolonged residual efficacy. These results indicate the potential of this insecticide as an addition to the arsenal of IRS products needed to maintain both control of malaria and resistance management of malaria-transmitting mosquitoes.

Indexed as

Mosquito ControlAnimalsAnophelesBenzamidesFluorocarbonsHumansInsecticide ResistanceInsecticidesMalariaMosquito VectorsPyrethrinsTanzania3-benzamido-N-(4-(perfluoropropan-2-yl)phenyl)benzamideBenzamidesFluorocarbonsInsecticidesPyrethrins

Identifiers

PMID33657179
PMCPMC7928474
OpenAlexW3135643485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.